Voyager Therapeutics Stock Performance
| VYGR Stock | USD 3.88 0.21 5.13% |
The entity has a beta of 0.9, which indicates possible diversification benefits within a given portfolio. Voyager Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Voyager Therapeutics is expected to follow. At this point, Voyager Therapeutics has a negative expected return of -0.59%. Please make sure to validate Voyager Therapeutics' skewness and day typical price , to decide if Voyager Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Voyager Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
Five Day Return (0.51) | Year To Date Return (35.01) | Ten Year Return (78.14) | All Time Return (78.14) |
1 | Disposition of 6500 shares by Robin Swartz of Voyager Therapeutics at 5.65 subject to Rule 16b-3 | 12/23/2024 |
2 | Disposition of 1191 shares by Todd Carter of Voyager Therapeutics at 5.13 subject to Rule 16b-3 | 01/14/2025 |
3 | Disposition of 5000 shares by Todd Carter of Voyager Therapeutics at 2.85 subject to Rule 16b-3 | 01/24/2025 |
4 | Disposition of 4358 shares by Fahey Sandell Jacquelyn of Voyager Therapeutics at 4.45 subject to Rule 16b-3 | 02/11/2025 |
5 | Disposition of 3894 shares by Robin Swartz of Voyager Therapeutics at 4.25 subject to Rule 16b-3 | 02/20/2025 |
6 | Acquisition by Jorgensen Nathan D. of 103000 shares of Voyager Therapeutics at 4.22 subject to Rule 16b-3 | 02/21/2025 |
7 | Acquisition by Robin Swartz of 71250 shares of Voyager Therapeutics subject to Rule 16b-3 | 02/24/2025 |
8 | VOYAGER ALERT Bragar Eagel Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Fi... | 02/25/2025 |
9 | Voyager Reports Positive Topline Data for Single Ascending Dose Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose Trial in Alzheimers Dise... | 03/03/2025 |
10 | New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach | 03/04/2025 |
11 | Voyager Therapeutics Q4 Earnings Snapshot | 03/11/2025 |
12 | Voyager Therapeutics Earns Overweight Rating from Cantor Fitzgerald | 03/12/2025 |
13 | Acquisition by Sandrock Alfred of 145000 shares of Voyager Therapeutics subject to Rule 16b-3 | 03/13/2025 |
14 | Acquisition by Pfreundschuh Peter P. of 60000 shares of Voyager Therapeutics at 7.6 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 70.4 M |
Voyager |
Voyager Therapeutics Relative Risk vs. Return Landscape
If you would invest 578.00 in Voyager Therapeutics on December 24, 2024 and sell it today you would lose (190.00) from holding Voyager Therapeutics or give up 32.87% of portfolio value over 90 days. Voyager Therapeutics is currently does not generate positive expected returns and assumes 3.7859% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Voyager, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Voyager Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Voyager Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Voyager Therapeutics, and traders can use it to determine the average amount a Voyager Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1548
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VYGR |
Estimated Market Risk
| 3.79 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.59 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Voyager Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Voyager Therapeutics by adding Voyager Therapeutics to a well-diversified portfolio.
Voyager Therapeutics Fundamentals Growth
Voyager Stock prices reflect investors' perceptions of the future prospects and financial health of Voyager Therapeutics, and Voyager Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Voyager Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.81) % | ||||
| Operating Margin | (6.10) % | ||||
| Current Valuation | (9.03 M) | ||||
| Shares Outstanding | 55.21 M | ||||
| Price To Earning | 5.62 X | ||||
| Price To Book | 0.71 X | ||||
| Price To Sales | 2.68 X | ||||
| Revenue | 80 M | ||||
| Gross Profit | (47.37 M) | ||||
| EBITDA | (83.29 M) | ||||
| Net Income | (65 M) | ||||
| Cash And Equivalents | 148.06 M | ||||
| Cash Per Share | 3.83 X | ||||
| Total Debt | 43.73 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.55 X | ||||
| Book Value Per Share | 5.48 X | ||||
| Cash Flow From Operations | (15.31 M) | ||||
| Earnings Per Share | (1.13) X | ||||
| Market Capitalization | 214.2 M | ||||
| Total Asset | 393.05 M | ||||
| Retained Earnings | (326.18 M) | ||||
| Working Capital | 227.02 M | ||||
| Current Asset | 195.89 M | ||||
| Current Liabilities | 23.93 M | ||||
About Voyager Therapeutics Performance
Assessing Voyager Therapeutics' fundamental ratios provides investors with valuable insights into Voyager Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Voyager Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 41.33 | 43.40 | |
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.17) | (0.17) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Voyager Therapeutics performance evaluation
Checking the ongoing alerts about Voyager Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Voyager Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Voyager Therapeutics generated a negative expected return over the last 90 days | |
| Voyager Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (65 M) with loss before overhead, payroll, taxes, and interest of (47.37 M). | |
| Voyager Therapeutics currently holds about 148.06 M in cash with (15.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.83. | |
| Roughly 64.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Acquisition by Pfreundschuh Peter P. of 60000 shares of Voyager Therapeutics at 7.6 subject to Rule 16b-3 |
- Analyzing Voyager Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Voyager Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Voyager Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Voyager Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Voyager Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Voyager Therapeutics' stock. These opinions can provide insight into Voyager Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.